Start Your Free Portfolio Tracker Today
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
On Aug 23, Zacks Investment Research downgraded
Patterson Companies ( PDCO - Analyst Report) to a Zacks Rank #3 (Hold) from Zacks Rank #2 (Buy) on the heels of a disappointing first-quarter fiscal 2014 results. Why the Downgrade?
Patterson reported a disappointing fiscal 2014 first quarter results, reflecting a challenging macro environment. The company delivered negative earnings surprises in 3 out of the last 4 quarters with a negative average surprise of 6.03%.
Patterson’s first-quarter fiscal 2014 earnings per share (EPS) of 45 cents per share was flat year over year and missed the Zacks Consensus Estimate by 3 cents. The company’s planned investment in IT lowered EPS by a cent. In the reported quarter, net income declined 3.4% to $45.9 million from $47.5 million in the year-ago period.
Moreover, revenues for the quarter dropped marginally by 1% to $880.1 million from $889.2 million reported in the first quarter of fiscal 2014. Revenues were considerably lower than the Zacks Consensus Estimate of $918 million.
Revenues from the core Patterson Dental declined 2.3% mainly due to an 11.7% drop in sales of the equipment and software offerings. However, management asserts that the dental equipment business faced difficult year-over-year comparisons and is confident that the business will deliver incremental returns for the rest of fiscal 2014 on the back of new products and rising demand.
PDCO’s margins too remained under pressure in the reported quarter. Moreover, despite its long-term benefits, the decision to divest certain non-core products from the Patterson Medical unit is likely to accelerate operating expenses in the near-term.
Despite these shortcomings, we note that the Veterinary business grew modestly in the quarter, reflecting a tailwind in the underlying market. Moreover, the Medical business is geared to grow in the long-term on the back of its advanced products portfolio as well as underlying favorable demographics. Other Stocks to Consider
Other medical stocks that are worth considering include MWI Veterinary Supply , Align Technology ( ALGN - Analyst Report) and The Cooper Companies ( COO - Analyst Report) . All these stocks carry a Zacks Rank #2 (Buy).